Insider buying last 90 days
No open-market insider purchases were filed for MRVI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MRVI insider filing, plotted on the chart in Gekko.Open MRVI in Gekko
NASDAQ: MRVI
Maravai LifeSciences (MRVI) Stock Analysis & Forecast
Oct 12 close
$7.06−0.38 (−5.1%)
Gekko Brief
AI summaryOct 12 closeMaravai LifeSciences has drawn analyst attention this week, with coverage noting an average "Hold" recommendation and an average price target of $6.83 from the five firms tracking the stock. This follows an August 6 report in which MRVI posted Q2 2026 revenue of $51.4 million, up 9% year over year, with TriLink growing 12% and Cygnus growing 3% for a fifth straight quarter of growth, alongside adjusted gross margin expansion of over 1,600 basis points to 58.9% and debt reduced to roughly $150 million.
Shares closed at $7.06, down 5.1% on the day, sitting between the 50-day average of $7.18 and the 200-day average of $4.97. The stock's one-month return stands at 8.1% and its six-month return at 130.7%. The GekkoIndex reads 59.7, placing MRVI in the Neutral zone, up 12.3 over five sessions. Price remains 14.6% above Gekko Fair Value of $6.16.
Looking ahead, MRVI next reports earnings on 5 November 2026, 24 days away and within a typical 20-trading-day holding window; the prior reaction to results was -2.8%, against an average absolute move of 13.9%. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, though one trailblazer holder is recorded. Seasonality over five years shows the next 20 trading days averaging -12.4%, rising in just 1 of those years, a contrast worth noting against the consensus target of $7.83.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Maravai LifeSciences price vs fair value
Close $7.06200-day averageGekko Fair Value $6.16
Maravai LifeSciences quick facts
- Market cap
- $1.95B
- P/E ratio
- —
- Forward P/E
- 370.4
- EPS, TTM
- −$0.53
- Revenue, TTM
- $208.8M
- Profit margin
- -37.1%
- Dividend yield
- —
- Beta
- 0.54
- Volume
- 1.25M avg 2.43M
- 1-year return
- +113.9%
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±12.7%
- 50-day average
- $7.18
- 200-day average
- $4.97
- Next earnings
- Nov 5 after close
- Shares outstanding
- 149.0M
Maravai LifeSciences swing-trade checklist
Maravai LifeSciences scores 0 supportive, 2 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive2 mixed3 headwinds
- Trendmixed
Averages disagree
Close $7.06 sits between the 50-day ($7.18) and 200-day ($4.97) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.7, Neutral
Reading 59.7 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
14.6% above
Price is 14.6% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−12.4% on average
From this point in the calendar, the next 20 trading days averaged −12.4% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Maravai LifeSciences stock chart and price history
Maravai LifeSciences closed at $7.06 on Oct 12, 2026, +113.9% over the past year, inside a 52-week range of $2.55 to $9.42.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.1%
- 3 months
- +8.4%
- 6 months
- +130.7%
- 1 year
- +113.9%
The full MRVI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MRVI in Gekko
Follow Maravai LifeSciences through every session
Put MRVI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MRVI in GekkoFree for 7 days. No credit card required.
About Maravai LifeSciences
Maravai LifeSciences supplies materials used in the development of drug treatments, diagnostic tests, vaccines, and studies of human disease. Its catalog includes nucleic acids used for both diagnostic and therapeutic purposes, antibody tools that flag impurities during biologic manufacturing, and methods for tracking protein expression in tissue samples. The company is particularly known for its work supporting nucleic acid-based therapies and testing used throughout biopharmaceutical production.
The business runs through two segments. One, Nucleic Acid Production, makes and sells materials for gene therapy, oligonucleotide and nucleoside chemistry, and molecular diagnostics, including reagents for building, labeling, and purifying DNA and RNA, as well as messenger RNA, plasmid DNA, and its CleanCap capping technology. The other, Biologics Safety Testing, provides analytical products such as custom antibody and assay development, HCP ELISA kits and related testing kits, reagents, and other services used to check for impurities in biologic manufacturing. Its customers include biopharmaceutical firms, other research-focused life sciences companies, academic institutions, and diagnostics companies.
Maravai LifeSciences was incorporated in 2020 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker MRVI.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- maravai.com
Maravai LifeSciences GekkoIndex: the smart money zone
Maravai LifeSciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.7, in the Neutral zone, up 12.3 points over five sessions.
59.7Neutral
Up 12.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 62 | +1.5% | +9.0% | ||
| Accumulation | 214 | +3.0% | +1.9% | ||
| Neutral (current zone) | 364 | 0.0% | +3.6% | ||
| Distribution | 38 | −4.8% | −6.7% | ||
| Selling | 4 | Too few readings yet | |||
Average MRVI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the MRVI price, zone by zone.Track MRVI in Gekko
Is Maravai LifeSciences stock overvalued? Gekko Fair Value
Maravai LifeSciences trades 14.6% above Gekko Fair Value of $6.16, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Maravai LifeSciences shares are worth, recalculated every trading day.
$6.16
Gekko Fair Value, Oct 10, 2026
14.6% Overvalued
At the end of Aug 2026 the price was 45.8% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MRVI in Gekko
Maravai LifeSciences insider and Congress trading
No open-market insider purchases were filed for Maravai LifeSciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MRVI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MRVI, plotted on the chart in Gekko.Open MRVI in Gekko
Buybacks
Maravai LifeSciences has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2025
- $111K
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds MRVI.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Maravai LifeSciences earnings: next date and track record
Maravai LifeSciences reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- −$0.06
- Revenue estimate
- $43.56M
2 of 8reports beat the EPS estimate
±13.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- MRVI reported Q2 2026 revenue of $51.4M, up 9% YoY, with TriLink growing 12% and Cygnus growing 3% (fifth consecutive quarter of growth). Adjusted gross margin expanded 1,600+ bps YoY to 58.9%, and adjusted EBITDA improved $19.1M to $8.7M. GMP consumables grew 55% YoY. Debt was refinanced and reduced to ~$150M, cut roughly in half since early 2026, with maturities extended to 2032. ModTail surpassed 125 active customers one year post-launch.
- Guidance
- Management expressed confidence in near-term outlook based on strong H1 momentum, improving customer visibility, and order conversion. GMP-grade ModTail launch expected later in 2026, targeting clinical manufacturing markets including cell and gene therapy.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.07 est −$0.07 | $51.44M est $48.67M | −2.8% |
| May 7, 2026 | $0.01 est −$0.05 | $65.84M est $53.00M | +23.1% |
| Feb 25, 2026 | −$0.04 est −$0.07 | $49.87M est $49.05M | +14.1% |
| Nov 6, 2025 | −$0.08 est −$0.06 | $41.63M est $49.06M | 0.0% |
| Aug 11, 2025 | −$0.08 est −$0.06 | $47.40M est $50.08M | +22.3% |
| May 12, 2025 | −$0.08 est −$0.07 | $46.85M est $44.01M | +4.0% |
| Mar 18, 2025 | −$0.06 est −$0.03 | $56.41M est $57.79M | −8.0% |
| Nov 7, 2024 | −$0.02 est −$0.01 | $65.20M est $56.64M | −36.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Maravai LifeSciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Maravai LifeSciences is $7.83, +10.9% from the last close, from 5 firms rating the stock in the last 90 days.
$7.83consensus 12-month target, +10.9% from the last close
Now $7.06Avg $7.83
Low $6.50High $9
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | TD Cowen | $9 | +27.5% |
| Sep 15 | Craig-Hallum | — | — |
| Sep 9 | UBS | $8 | +13.3% |
| Aug 7 | Wells Fargo | $6.50 | −7.9% |
| Aug 7 | William Blair | — | — |
+3.6%average 20-day move after past Neutral readings
−12.4%average move over the next 20 trading days in the last 5 years
±6.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Maravai LifeSciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Maravai LifeSciences averaged −12.4% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 2 of 5 |
| Next 10 trading days | −5.8% | 2 of 5 |
| Next 15 trading days | −5.8% | 1 of 5 |
| Next 20 trading days | −12.4% | 1 of 5 |
| Next 30 trading days | −18.8% | 1 of 5 |
For scale, MRVI’s typical 20-trading-day move in either direction is about 12.7%.
Maravai LifeSciences market cap and key statistics
Maravai LifeSciences’s market cap is $1.95B and revenue of $208.8M over the last twelve months.
Valuation
- Market cap
- $1.95B
- Forward P/E
- 370.4
- EPS, TTM
- −$0.53
- Gekko Fair Value
- $6.16
Trading
- Volume
- 1.25M
- Avg volume, 20 days
- 2.43M
- 52-week high
- $9.42
- 52-week low
- $2.55
- Shares outstanding
- 149.0M
Financials
- Revenue, TTM
- $208.8M
- Profit margin
- -37.1%
- Return on equity
- -33.1%
- Quarterly earnings growth, YoY
- −32.7%
Risk and income
- Beta
- 0.54
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±12.7%
Maravai LifeSciences stock news this week
1 headline about Maravai LifeSciences from the past week, newest first, each linking to the publisher.
Maravai LifeSciences peers
Maravai LifeSciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Maravai LifeSciences stock FAQ
What is Maravai LifeSciences’s market cap?
Maravai LifeSciences’s market cap is $1.95B at the Oct 12, 2026 close of $7.06, with 149.0M shares outstanding.
What is the Maravai LifeSciences stock forecast?
The consensus analyst 12-month price target for Maravai LifeSciences is $7.83, +10.9% from the last close. Of the 5 firms that rated the stock in the last 90 days, 3 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Maravai LifeSciences stock overvalued or undervalued?
On Gekko’s estimate Maravai LifeSciences is overvalued: the Oct 12, 2026 close of $7.06 is 14.6% above Gekko Fair Value of $6.16. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Maravai LifeSciences report earnings next?
Maravai LifeSciences is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of −$0.06 per share on revenue of $43.56M. Maravai LifeSciences beat the earnings estimate in 2 of its last 8 reports, moving 13.9% on average across the report.
What is Maravai LifeSciences’s 52-week high and low?
Maravai LifeSciences’s 52-week high is $9.42 and its 52-week low is $2.55; it closed at $7.06 on Oct 12, 2026, +113.9% over the past year. Over the last five years the shares peaked at $46.43 on Nov 3, 2021.
Is Maravai LifeSciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 5 items with data read as supportive, 2 as mixed (trend and gekkoindex) and 3 as headwinds (fair value, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Maravai LifeSciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.